BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Authors » John Fox

John Fox

Articles

ARTICLES

Epigenetic mechanisms can contribute to resistance in melanoma

July 10, 2018
By John Fox

A study by scientists at New Zealand's Otago University has opened the door to the discovery of new biomarkers that potentially predict whether melanoma patients will respond to treatment with novel checkpoint inhibitor immunotherapies.


Read More

Epigenetic mechanisms can contribute to resistance in melanoma for patients

July 6, 2018
By John Fox

Epigenetic mechanisms can contribute to resistance in melanoma

July 6, 2018
By John Fox
A study by scientists at New Zealand's Otago University has opened the door to the discovery of new biomarkers that potentially predict whether melanoma patients will respond to treatment with novel checkpoint inhibitor immunotherapies.
Read More

Cell death discovery paves way for new treatments

July 5, 2018
By John Fox
The discovery of how human cells are triggered to undergo cell death could have major implications for development of new drugs for treating cancer, stroke and tissue injury, and immune disorders, according to a study by Australian researchers.
Read More

Cell death discovery paves way for new treatments

July 5, 2018
By John Fox
The discovery of how human cells are triggered to undergo cell death could have major implications for development of new drugs for treating cancer, stroke and tissue injury, and immune disorders, according to a study by Australian researchers.
Read More

Cell death discovery paves way for new treatments

July 2, 2018
By John Fox

First new influenza drug developed using viral genes

June 27, 2018
By John Fox
HONG KONG – A team of researchers from the University of Hong Kong (HKU) has developed a novel strategy for the prevention and treatment of influenza virus infection, which they then demonstrated to be effective in mice.
Read More

Mutation links bipolar disorder to mitochondrial dysfunction

June 20, 2018
By John Fox
Mutations in the adenine nucleotide translocase type 1 (ANT1) gene may confer a risk for bipolar disorder through a complex interaction between serotonin and mitochondri al signaling within the brain, a new Japanese study suggests.
Read More

Mutation links bipolar disorder to mitochondrial dysfunction

June 15, 2018
By John Fox

Mutation links bipolar disorder to mitochondrial dysfunction

June 15, 2018
By John Fox
Mutations in the adenine nucleotide translocase type 1 (ANT1) gene may confer a risk for bipolar disorder through a complex interaction between serotonin and mitochondrial signaling within the brain, a new Japanese study suggests.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 31, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing